The PMWC 2021 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
Confirmed Presenting Companies:
Dan is Chief Medical Officer at IGM Biosciences, focused on the development of novel engineered therapeutics. Prior to IGM, he was Vice President, Global Head of Cancer Immunotherapy in Development at Genentech/Roche, contributing to over 20 cancer immunotherapy programs. He is currently co-chair of the Cancer Immunotherapy Committee, an arm of the Cancer Research Institute (CRI), and serves on the Board of Directors for the Society for Immunotherapy of Cancer (SITC). His publications include the often referenced Chen and Mellman manuscripts, “Elements of cancer immunity and the cancer-immune set point” and “Oncology meets Immunology: the Cancer-Immunity Cycle.” Dan received his BS degree in Biology from MIT, MD PhD from USC (Microbiology & Immunology) and completed medicine and medical oncology training at Stanford. He also completed a post-doctoral fellowship with Mark Davis (Immunology/Stanford) and then stayed on to run the metastatic melanoma clinic at the Stanford Cancer Center. Dan continued to care for melanoma patients at Stanford until 2016.
Emerging Therapeutics Showcase:
IGM Biosciences is the world leader in a new class of therapeutic antibodies.
Dr. Iyer’s professional experience spans the academic Pharma and biotechnology industry. At Quest Diagnostics, she is responsible for leading the Pharma Services business including providing strategic direction to the Precision Medicine/Companion Dx business, working closely with other teams to align with the market needs. Dr Iyer leads Programs with Pharma companies that include Custom Testing, Commercialization of CDx tests, REMS and End -End services including ssPMA projects. Prior to joining Quest Diagnostics, Dr Iyer was at AZ as Director, Commercial for Companion Diagnostics, at Molecular Health as Director of Product Marketing and with Qiagen Inc. leading their North American Molecular Diagnostics marketing and Global Product Management teams.
Emerging Therapeutics Showcase:
Quest Diagnostics is the Largest Reference laboratory with products and services that benefit patients, health care providers, Pharmaceutical companies , Life insurance companies and employers. Quest Diagnostics empowers people to take action to improve health outcomes.
Diagnostics is Essential to Precision Medicine
As the world's leading provider of diagnostic testing, we will share our experience in supporting the hope of new therapies that can bring effective treatments in the market. We will highlight real world experience related to the ordering behavior, testing practices and barriers of the physician community and their typical preferences and practices in treating patients. Ensuring the test is integrated into these patterns is often critical for the success.